Related Experiment Video
Updated: Jan 30, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Fixed Dose Combination Formulations: Multilayered Platforms Designed for the Management of Cardiovascular Disease
G P Andrews1, S Li1, A Almajaan1
1Pharmaceutical Engineering Group, School of Pharmacy , Queen's University , Belfast BT9 , U.K.
Insights
This study developed a novel bilayer drug delivery system for biphasic release of simvastatin and aspirin. The system successfully achieved delayed simvastatin release and immediate aspirin release, offering a new platform for fixed-dose combination therapies.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
- Cardiovascular Pharmacology
Background:
- Hyperlipidemia is a major risk factor for cardiovascular diseases (CVDs).
- Simvastatin, a common statin for hyperlipidemia, undergoes extensive metabolism by CYP450 3A4/3A5 enzymes.
- Co-administration of antihypertensives and anticoagulants is common in CVD management.
Purpose of the Study:
- To design and develop a bilayer drug delivery system for biphasic release of simvastatin and aspirin.
- To create a fixed-dose combination platform for managing cardiovascular risk factors.
Main Methods:
- Development of a delayed-release platform using anionic polymers and hot-melt extrusion for simvastatin.
- Formulation of an immediate-release layer with Kollidon VA64 for aspirin.
- Manufacturing of bilayer tablets and coextrudates, followed by dissolution testing.
Main Results:
- The optimized formulation successfully delayed the release of simvastatin.
- An immediate-release layer for aspirin was effectively developed.
- Bilayer systems demonstrated biphasic release profiles for both drugs.
Conclusions:
- The developed bilayer system provides a viable platform for biphasic drug delivery.
- This approach can be extended to fixed-dose combinations of various medications.
- The system offers potential for improved therapeutic outcomes in cardiovascular disease management.
Abstract:
Hyperlipidaemia is considered as one of the main risk factors associated with cardiovascular diseases (CVDs). Among different lipid-lowering agents used to manage hyperlipidaemia, statins are highly prescribed for management of hyperlipidaemia with simvastatin being one of the most common. Simvastatin is susceptible to extensive metabolism by CYP450 3A4 and 3A5, which are expressed both in the liver and the gastrointestinal tract. Nevertheless, the localization of these enzymes is site-dependent with lower concentration at the distal/proximal regions of the small intestine/colon. In addition to statins, medications such as antihypertensive agents and anticoagulants are introduced as adjuvants, for the treatment of cardiovascular disease. The aim of this study was to design a bilayer delivery system capable of delivering biphasic release of simvastatin and aspirin, within a fixed dose combination. A delayed release platform based on a combination of anionic polymers prepared using hot-melt extrusion was developed to delay the release of simvastatin. An optimized formulation tested for dissolution performance clearly demonstrated an ability to delay the release of simvastatin. In addition, an immediate release layer based on Kollidon VA64 was successfully developed to deliver aspirin. Both formulations were then manufactured as a bilayer drug delivery system (tablets and coextrudates), and the release performance was examined. On the basis of the obtained results, these formulations may be used as a platform for delivering a wide range of medications in a biphasic manner.
Related Concept Videos
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Design Example: Managing Concrete Workability
Bioavailability Study Design: Single Versus Multiple Dose Studies
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

